IN THE NEWS
Cardiac Science Announces Data Connectivity with LUMEDX
Innovative firms partner to improve workflow and data connectivity for Cardiac RehabilitationBOTHELL, WA – Cardiac Science Corporation, a global leader in advanced cardiac monitoring and defibrillation products, announced today that its new cardiac rehab system, Q-Tel RMS® 3.0, now has seamless connectivity with LUMEDX CardioWellnessTM data management software.
The integration of rehabilitation data from the Q-Tel RMS 3.0 system into CardioWellness enables the best possible treatment decisions. The combination allows caregivers to seamlessly integrate data from the Q-Tel RMS 3.0 rehabilitation system into CardioWellness, creating a comprehensive diagnosis and treatment plan tuned specifically to the patient’s gender specific needs. By applying this gender-specific understanding of the patient’s disease state to the rehabilitation treatment, outcomes can be improved.
“Cardiac Science is dedicated to helping its customers improve their workflows and improve access to data, facilitating the best possible treatment decisions,” said René Mitchell, director of diagnostic marketing at Cardiac Science. “In response to feedback from clinicians, the Q-Tel RMS 3.0 features enhanced connectivity capabilities to improve rehab center workflow, while maintaining the heritage of reliability and high performance of the Q-Tel family of rehabilitation management systems. We believe that this collaboration with LUMEDX will improve patient care and better meet the needs of our customers.”
“CardioWellness can help facilities grow their gender-specific cardiovascular care programs with its sophisticated database for tracking patients from risk assessment through treatment,” said Randy Marc Lasnick, director of marketing at LUMEDX Corporation. “Research has shown that gender-specific care can provide patients with better outcomes. We believe that by providing a direct link between CardioWellness and Q-Tel RMS 3.0, the leading cardiac rehabilitation system, we can provide greater value to these facilities by bringing an added layer of critical rehab data into the clinical decision making process.”
Frost & Sullivan, the global growth consulting company, has awarded Cardiac Science its 2007 award for Global Excellence in ECG Monitoring, recognizing Cardiac Science’s superior leadership and vision to provide superior healthcare solutions in the cardiac monitoring market.
For more information about the Q-Tel RMS 3.0, please call 800.679.8703.
About LUMEDX
Founded in 1990, LUMEDX is the market leader in developing end-to-end cardiovascular information and imaging systems. Providing consulting services, training, and the CardioStar™ software suite—the most comprehensive suite of fully integrated cardiovascular information tools—LUMEDX delivers complete clinical and business solutions for heart centers.
About CardioWellness
CardioWellness is a comprehensive set of tools and support programs to help heart centers grow their own successful gender-specific CV centers. CardioWellness recognizes the differences in presentation, diagnostic testing, risk assessment, and outcomes for men and women. These differences are built into the way patients are diagnosed, treated, and tracked throughout the continuum of care.
About Q-Tel RMS 3.0
The Q-Tel RMS system is a state-of-the-art, comprehensive cardiac monitoring and data management system developed to meet the needs of cardiac rehabilitation programs. Designed with efficient workflow and integration to EMR and HIS systems in mind, the Q-Tel family of Rehabilitation Management Systems is designed to enable the best possible treatment decisions.
About Cardiac Science
Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT
For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif